EA201290305A1 - Производные трициклического пиразоламина - Google Patents

Производные трициклического пиразоламина

Info

Publication number
EA201290305A1
EA201290305A1 EA201290305A EA201290305A EA201290305A1 EA 201290305 A1 EA201290305 A1 EA 201290305A1 EA 201290305 A EA201290305 A EA 201290305A EA 201290305 A EA201290305 A EA 201290305A EA 201290305 A1 EA201290305 A1 EA 201290305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazolamine
tricyclic
derivatives
diseases
cancer
Prior art date
Application number
EA201290305A
Other languages
English (en)
Russian (ru)
Inventor
Паскаль Гайяр
Изабелль Жанклод-Эттер
Венсан Помель
Эрик Себий
Синисами Джейапракашнарайянан
Матильд Мюзерелль
Original Assignee
Мерк Сероно С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Сероно С.А. filed Critical Мерк Сероно С.А.
Publication of EA201290305A1 publication Critical patent/EA201290305A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
EA201290305A 2009-11-13 2010-11-12 Производные трициклического пиразоламина EA201290305A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09175933 2009-11-13
US26185409P 2009-11-17 2009-11-17
PCT/EP2010/067412 WO2011058149A1 (en) 2009-11-13 2010-11-12 Tricyclic pyrazol amine derivatives

Publications (1)

Publication Number Publication Date
EA201290305A1 true EA201290305A1 (ru) 2012-12-28

Family

ID=41796476

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290305A EA201290305A1 (ru) 2009-11-13 2010-11-12 Производные трициклического пиразоламина

Country Status (14)

Country Link
US (1) US9073940B2 (enExample)
EP (1) EP2499146B1 (enExample)
JP (1) JP5735526B2 (enExample)
KR (1) KR20130049766A (enExample)
CN (1) CN102695710B (enExample)
AR (1) AR078979A1 (enExample)
AU (1) AU2010317883B2 (enExample)
CA (1) CA2778174C (enExample)
EA (1) EA201290305A1 (enExample)
ES (1) ES2607952T3 (enExample)
IL (1) IL219602A (enExample)
MX (1) MX2012005518A (enExample)
WO (1) WO2011058149A1 (enExample)
ZA (1) ZA201202641B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2752173C2 (ru) * 2014-06-23 2021-07-23 Арес Трейдинг С.А. Пиразоловые соединения в качестве модуляторов fshr и пути их применения

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9044451B2 (en) 2010-07-19 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
JP6367211B2 (ja) * 2012-11-16 2018-08-01 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体
WO2014121901A1 (en) 2013-02-07 2014-08-14 Merck Patent Gmbh Polymorphic forms
RU2663898C2 (ru) * 2013-06-24 2018-08-13 Мерк Патент Гмбх Пиразольные соединения в качестве модуляторов fshr и их применение
AU2016313263B2 (en) 2015-08-26 2021-02-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Condensed tricyclic compounds as protein kinase inhibitors
TW201837026A (zh) 2017-01-10 2018-10-16 德商拜耳廠股份有限公司 作為除害劑之雜環衍生物(二)
KR102515694B1 (ko) 2017-01-10 2023-03-29 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
CN108434150B (zh) * 2018-02-09 2020-03-10 天津医科大学总医院 Zstk474用于制备ean治疗药物的应用
EP3608326A1 (en) * 2018-08-10 2020-02-12 Irbm S.P.A. Tricyclic inhibitors of hepatitis b virus
CN113754678B (zh) * 2020-06-02 2023-03-10 江苏恒瑞医药股份有限公司 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用
CN113754685B (zh) * 2020-06-02 2023-06-16 江苏恒瑞医药股份有限公司 二氢硫代色烯并吡唑类衍生物、其制备方法及其在医药上的应用
BR112022026904A2 (pt) 2020-07-02 2023-01-24 Bayer Ag Derivados de heterocicleno como agentes de controle de pragas
WO2022007924A1 (zh) * 2020-07-09 2022-01-13 江苏恒瑞医药股份有限公司 氧杂氮杂双环类衍生物、其制备方法及其在医药上的应用
WO2022022630A1 (zh) 2020-07-29 2022-02-03 江苏恒瑞医药股份有限公司 氧杂氮杂螺环类衍生物、其制备方法及其在医药上的应用
GB202117511D0 (en) * 2021-12-03 2022-01-19 Ionctura Sa Treatment regimens
FI4313058T3 (fi) * 2021-03-29 2025-04-30 Ionctura Sa Roginolisibia käsittävä koostumus ja annosteluohjelma syövän tai tulehdus- tai autoimmunisairauden hoitoon
JP2024511836A (ja) * 2021-03-29 2024-03-15 アイオンクチュラ・ソシエテ・アノニム 膵臓癌の治療のためのpi3k-デルタ阻害剤
CN114524827B (zh) * 2022-02-22 2024-07-09 深圳市儿童医院 一种用于治疗神经重症的吡唑衍生物及其应用
CN114524828B (zh) * 2022-02-22 2024-07-09 深圳市儿童医院 一种用于治疗神经重症的噻唑衍生物及其应用
CN115491252B (zh) * 2022-09-29 2023-05-02 江苏四新界面剂科技有限公司 一种宝石切割用低泡润湿剂及其制备方法
WO2024184266A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and hdac inhibitor in the treatment of haematological malignancy
JP2026510567A (ja) 2023-03-03 2026-04-08 アイオンクチュラ・ソシエテ・アノニム 血液悪性腫瘍の治療におけるロギノリシブ及びbcl-2阻害剤の組み合わせ
GB202308807D0 (en) 2023-06-13 2023-07-26 Ionctura Sa Combinations
AU2024357109A1 (en) 2023-10-06 2026-03-12 Ionctura Sa Combination of roginolisib with a malt1-gls inhibitor
WO2025195504A1 (zh) * 2024-03-22 2025-09-25 复旦大学附属中山医院 三环骨架化合物及其在制备抗肿瘤药物中的应用
TWI926701B (zh) * 2024-03-22 2026-05-21 復旦大學附屬中山醫院 三環骨架化合物及其在製備抗腫瘤藥物的應用
GB202418087D0 (en) 2024-12-10 2025-01-22 Ionctura Sa Biomarkers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816467A (en) 1987-01-09 1989-03-28 Farmitalia Carlo Erba S.R.L Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use
GB8814586D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Tricyclic 3-oxo-propanenitrile derivatives & process for their preparation
GB8907799D0 (en) * 1989-04-06 1989-05-17 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in the treatment of rheumatoid arthritis and other autoimmune diseases
GB8916290D0 (en) * 1989-07-17 1989-08-31 Erba Carlo Spa Heteroaryl-3-oxo-propanenitrile derivatives useful in stimulating myelopoiesis
JP3542826B2 (ja) 1994-07-11 2004-07-14 帝国臓器製薬株式会社 新規な二環式化合物縮合[2,1−d]イソキサゾール−3−カルボン酸誘導体
GB9720901D0 (en) * 1997-10-01 1997-12-03 Pharmacia & Upjohn Spa Condensed benzothiopyranic compounds
FR2800375B1 (fr) * 1999-11-03 2004-07-23 Sanofi Synthelabo Derives tricycliques d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
MXPA05000453A (es) 2002-07-10 2005-03-23 Applied Research Systems Derivados de benceno fusionados a azolidinona-vinilo.
WO2004056820A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
GB0305152D0 (en) 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) 2003-08-28 2003-10-01 Novartis Ag Organic compounds
US7691888B2 (en) 2004-10-07 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-indazole
CA2633500A1 (en) 2005-12-20 2007-07-05 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
WO2008035356A2 (en) 2006-09-20 2008-03-27 Glenmark Pharmaceuticals Limited Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
WO2009010824A1 (en) 2007-07-13 2009-01-22 Glenmark Pharmaceuticals, S.A. Dihydrochromenopyrazole derivatives as vanilloid receptor ligands
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
ES2480994T3 (es) 2008-03-31 2014-07-29 Genentech, Inc. Compuestos de tipo benzopirano y benzoxepina inhibidores de PI3K y métodos de uso

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2752173C2 (ru) * 2014-06-23 2021-07-23 Арес Трейдинг С.А. Пиразоловые соединения в качестве модуляторов fshr и пути их применения

Also Published As

Publication number Publication date
CA2778174C (en) 2018-02-20
US9073940B2 (en) 2015-07-07
JP5735526B2 (ja) 2015-06-17
CA2778174A1 (en) 2011-05-19
AR078979A1 (es) 2011-12-14
ZA201202641B (en) 2013-06-26
EP2499146A1 (en) 2012-09-19
JP2013510825A (ja) 2013-03-28
ES2607952T3 (es) 2017-04-04
US20120238545A1 (en) 2012-09-20
AU2010317883A1 (en) 2012-05-03
IL219602A0 (en) 2012-07-31
KR20130049766A (ko) 2013-05-14
EP2499146B1 (en) 2016-09-21
CN102695710A (zh) 2012-09-26
AU2010317883B2 (en) 2015-08-06
WO2011058149A1 (en) 2011-05-19
MX2012005518A (es) 2012-06-19
CN102695710B (zh) 2015-08-19
IL219602A (en) 2017-04-30

Similar Documents

Publication Publication Date Title
EA201291143A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
EA201070328A1 (ru) Соединения триазолопиридина и их применение в качестве ингибиторов ask
EA201300730A1 (ru) Производные индазолилтриазола
CY1120866T1 (el) Παρεμποδιστες dna-pk
UA109667C2 (xx) Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази
EA201590850A1 (ru) Трициклические конденсированные производные тиофена как ингибиторы jak
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
MX352928B (es) Compuestos de piridazina-amida.
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA201071057A1 (ru) Производные азетидина и циклобутана как ингибиторы jak-киназ
EA201290807A1 (ru) Циклобутановые и метилциклобутановые производные в качестве ингибиторов янус-киназы
DK2250172T3 (da) Pyrrolopyrazinkinaseinhibitorer
EA201400735A1 (ru) Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EA201491012A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201290744A1 (ru) Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
MX343561B (es) Compuestos de imidazolpiridazina.
CL2012001821A1 (es) Compuestos derivados de 5-alquinil-pirimidinas, inhibidores de quinasas; composiciones farmaceuticas que los contienen; y su uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
UA112795C2 (uk) Біциклічні піразинонові похідні
PH12012502410A1 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
MX349548B (es) Compuestos de tienopirimidina.
EA201200087A1 (ru) 2-карбоксамиды циклоаминомочевин, которые являются ингибиторами pi3k